Corix Bioscience (Corix Bioscience) Cash-to-Debt : 7.22 (As of Sep. 2017)

View and export this data going back to 2008. Start your Free Trial

What is Corix Bioscience Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Corix Bioscience's cash to debt ratio for the quarter that ended in Sep. 2017 was 7.22.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Corix Bioscience could pay off its debt using the cash in hand for the quarter that ended in Sep. 2017.

The historical rank and industry rank for Corix Bioscience's Cash-to-Debt or its related term are showing as below:

CXBS's Cash-to-Debt is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.93
* Ranked among companies with meaningful Cash-to-Debt only.

Corix Bioscience Cash-to-Debt Historical Data

The historical data trend for Corix Bioscience's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Corix Bioscience Cash-to-Debt Chart

Corix Bioscience Annual Data

Trend

Jan09

Jan10

Jan11

Jan12

Jan13

Jan14

Jan15

Dec16

Cash-to-Debt

Get a 7-Day Free Trial

N/A

Corix Bioscience Quarterly Data
	Oct12	Jan13	Apr13	Jul13	Oct13	Jan14	Apr14	Jul14	Oct14	Jan15	Apr15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Cash-to-Debt	Get a 7-Day Free Trial															0.02	-	N/A	7.58	7.22

Competitive Comparison of Corix Bioscience's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corix Bioscience's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's Cash-to-Debt falls into.

Corix Bioscience Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Corix Bioscience's Cash to Debt Ratio for the fiscal year that ended in Dec. 2016 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.002	/	(0.074	+	5.077)
	=	0.00

Corix Bioscience's Cash to Debt Ratio for the quarter that ended in Sep. 2017 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.361	/	(0.05	+	0)
	=	7.22

Corix Bioscience (GREY:CXBS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Corix Bioscience Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Corix Bioscience's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Corix Bioscience (Corix Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Corix Bioscience Inc (GREY:CXBS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085

Website

http://www.corixbioscience.com

Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.

Corix Bioscience (Corix Bioscience) Headlines

No Headlines